Show simple item record

dc.contributor.authorMatutes, Een_US
dc.contributor.authorTaylor, GPen_US
dc.contributor.authorCavenagh, Jen_US
dc.contributor.authorPagliuca, Aen_US
dc.contributor.authorBareford, Den_US
dc.contributor.authorDomingo, Aen_US
dc.contributor.authorHamblin, Ren_US
dc.contributor.authorKelsey, Sen_US
dc.contributor.authorMir, Nen_US
dc.contributor.authorReilly, JTen_US
dc.date.accessioned2018-09-25T10:33:26Z
dc.date.issued2001-06en_US
dc.identifier3en_US
dc.identifier.citationBRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 pp. 779 - 784en_US
dc.identifier.issn0007-1048en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2861
dc.identifier.doi10.1046/j.1365-2141.2001.02794.xen_US
dc.description.abstractAdult T-cell leukaemia lymphoma (ATLL) is an aggressive disease caused by the human T-lymphotropic virus 1 (HTLV-I) with a short survival, Responses to interferon alpha (IFN-alpha) and zidovudine (AZT) have been documented but not with long-term follow-up. We treated 15 ATLL, patients with IFN and AZT. Eleven patients had acute ATLL, two had lymphoma and two smouldering ATLL, with progression. The main features were: organomegaly (14), skin lesions (10), high white blood cell (WBC) count (11) and hypercalcaemia (9). Eleven patients had previously received chemotherapy and one had received an autograft. Al the time of the study, seven patients had progressive disease and eight were in partial or complete clinical remission. Responses (PR) lasting 2+ to 44+ months were seen in 67%; 26% did not respond (NR) and one patient was not evaluable. Hypercalcaemia predicted a poor outcome but differences were not significant. Eight of the 15 patients have died 3-41 months from diagnosis. Median survival for the 15 patients was 18 months. Survival of the NR ranged from 4 to 20 months; six PR patients are alive 8-82 months from diagnosis. The differences in survival between NR (median: 6 months) and PR (55% of patients alive at 4 years) were statistically significant (P = 0.002). In conclusion, IFN and AZT improves the outcome of ATLL patients and helps maintain responses.en_US
dc.format.extent779 - 784en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherBLACKWELL SCIENCE LTDen_US
dc.titleInterferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patientsen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1046/j.1365-2141.2001.02794.xen_US
rioxxterms.licenseref.startdate2001-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBRITISH JOURNAL OF HAEMATOLOGYen_US
pubs.notesaffiliation: Matutes, E (Reprint Author), Royal Marsden Hosp NHS Trust, Inst Canc Res, Dept Haematol, Fulham Rd, London SW3 6JJ, England. Royal Marsden Hosp NHS Trust, Inst Canc Res, Dept Haematol, London SW3 6JJ, England. Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, London SW7 2AZ, England. St Bartholomews Hosp, Dept Haematol, London, England. Royal London Hosp, GKT Sch Med, Dept Haematol, London, England. Birmingham City Hosp NHS Trust, Dept Haematol, Birmingham, W Midlands, England. Bellvitge Hosp, Dept Haematol, Barcelona, Spain. Mayday Hosp, Dept Haematol, London, England. Lewisham Univ Hosp, Dept Haematol, London, England. Royal Hallamshire Hosp, Dept Haematol, London, England. keywords: HTLV-I; leukaemia; interferon; zidovudine; survival keywords-plus: LEUKEMIA-LYMPHOMA; HTLV-I; SPONTANEOUS REMISSION; MALIGNANCIES research-areas: Hematology web-of-science-categories: Hematology researcherid-numbers: pagliuca, antonio/F-8886-2013 orcid-numbers: pagliuca, antonio/0000-0003-2519-0333 number-of-cited-references: 23 times-cited: 63 usage-count-last-180-days: 0 usage-count-since-2013: 2 journal-iso: Br. J. Haematol. doc-delivery-number: 444YR unique-id: ISI:000169428600033 oa: gold_or_bronze da: 2018-09-25en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume113en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record